Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From EQRx, Inc.

Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs

Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.

Deal Watch Business Strategies

2021 Venture Investment Was Bullish – Will 2022 Be The Same?

The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?

Growth Commercial

The IPO Party Is Over – How Bad Is The Hangover?

Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?

Financing Market Intelligence

Lilly/Innovent Experience Show Hurdles Remaining For Chinese PD-1 Inhibitors

China has fielded several homegrown checkpoint inhibitors, using lower cost as an argument for the US market, but sintilimab – a key test case – has underscored FDA skepticism.

Cancer ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register